[go: up one dir, main page]

PE20080977A1 - Farmaco combinado - Google Patents

Farmaco combinado

Info

Publication number
PE20080977A1
PE20080977A1 PE2007001354A PE2007001354A PE20080977A1 PE 20080977 A1 PE20080977 A1 PE 20080977A1 PE 2007001354 A PE2007001354 A PE 2007001354A PE 2007001354 A PE2007001354 A PE 2007001354A PE 20080977 A1 PE20080977 A1 PE 20080977A1
Authority
PE
Peru
Prior art keywords
cancer
pharmacy
combined
hormonal
therapeutic agent
Prior art date
Application number
PE2007001354A
Other languages
English (en)
Inventor
Yoshikazu Ohta
Toshiya Tamaru
Shinji Takagi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20080977A1 publication Critical patent/PE20080977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A UN METODO TERAPEUTICO QUE HACE REFERENCIA A LA ADMINISTRACION DE UN INHIBIDOR DE HER2 Y UN AGENTE TERAPEUTICO HORMONAL O ANTICANCERIGENO; DONDE EL INHIBIDOR DE HER2 TIENE UN ESQUELETO DE PIRROLOPIRIMIDINA, O PIRAZOLOPIRIMIDINA REPRESENTADO POR I; EN EL QUE W ES CR1 O N; R1 ES H, C, N U O; A ES ARILO O HETEROARILO; X1 ES O, SO2, ENTRE OTROS; R2 ES H, O UN GRUPO SUSTITUIDO A TRAVES DE UN ATOMO DE CARBONO O AZUFRE. Y EL AGENTE TERAPEUTICO HORMONAL O ANTICANCERIGENO ES FLUBESTRANT, CETUXIMAB, PACLITAXEL, ENTRE OTROS. DICHA COMBINACION DE FARMACOS ES DE UTILIDAD EN EL TRATAMIENTO DE CANCER
PE2007001354A 2006-10-06 2007-10-05 Farmaco combinado PE20080977A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006275841 2006-10-06
JP2007057902 2007-03-07

Publications (1)

Publication Number Publication Date
PE20080977A1 true PE20080977A1 (es) 2008-09-05

Family

ID=39283276

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001354A PE20080977A1 (es) 2006-10-06 2007-10-05 Farmaco combinado

Country Status (23)

Country Link
US (1) US20100008912A1 (es)
EP (2) EP2359825A2 (es)
JP (1) JP2010505745A (es)
KR (1) KR20090094804A (es)
CN (1) CN101553222A (es)
AR (1) AR063152A1 (es)
AU (1) AU2007307489A1 (es)
BR (1) BRPI0717477A2 (es)
CA (1) CA2665692A1 (es)
CL (1) CL2007002878A1 (es)
CO (1) CO6180429A2 (es)
CR (1) CR10759A (es)
EA (1) EA200970353A1 (es)
EC (1) ECSP099311A (es)
GE (1) GEP20115218B (es)
IL (1) IL197883A0 (es)
MA (1) MA30815B1 (es)
MX (1) MX2009003660A (es)
NO (1) NO20091628L (es)
PE (1) PE20080977A1 (es)
TN (1) TN2009000119A1 (es)
TW (1) TW200823218A (es)
WO (1) WO2008044782A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20105024B (en) * 2004-06-02 2010-06-25 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20100183604A1 (en) 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
US8946239B2 (en) * 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
KR101592258B1 (ko) * 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
US10317014B2 (en) * 2016-08-09 2019-06-11 Baker Hughes, A Ge Company, Llc Flow variation system
WO2021188685A1 (en) * 2020-03-17 2021-09-23 Microvention, Inc. Liquid embolics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
KR20050057072A (ko) * 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
GEP20105024B (en) * 2004-06-02 2010-06-25 Takeda Pharmaceuticals Co Fused heterocyclic compound
CA2569139A1 (en) 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
CA2578384A1 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
JP2006275841A (ja) 2005-03-30 2006-10-12 Taiheiyo Cement Corp セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja) 2005-08-25 2007-03-08 Seiko Epson Corp 画像形成装置

Also Published As

Publication number Publication date
CA2665692A1 (en) 2008-04-17
MX2009003660A (es) 2009-04-22
AR063152A1 (es) 2008-12-30
TW200823218A (en) 2008-06-01
EP2063895A2 (en) 2009-06-03
CR10759A (es) 2009-05-27
EP2359825A2 (en) 2011-08-24
NO20091628L (no) 2009-06-26
IL197883A0 (en) 2009-12-24
EA200970353A1 (ru) 2009-10-30
MA30815B1 (fr) 2009-10-01
JP2010505745A (ja) 2010-02-25
WO2008044782A3 (en) 2008-12-11
WO2008044782A2 (en) 2008-04-17
AU2007307489A1 (en) 2008-04-17
GEP20115218B (en) 2011-05-25
TN2009000119A1 (en) 2010-10-18
BRPI0717477A2 (pt) 2015-06-16
CN101553222A (zh) 2009-10-07
ECSP099311A (es) 2009-06-30
CL2007002878A1 (es) 2008-08-01
CO6180429A2 (es) 2010-07-19
KR20090094804A (ko) 2009-09-08
US20100008912A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
PE20080977A1 (es) Farmaco combinado
UY30905A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
BRPI0617412B8 (pt) anticorpo antiglipicano-3, agente anticâncer compreendendo o mesmo, bem como seu uso e seu processo de produção
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
ECSP088982A (es) Métodos para tratar enfermedades autoinmunes utilizando una molécula de fusión taci-ig
BRPI0516299B8 (pt) formulação farmacêutica e uso de uma formulação farmacêutica
GT200500230A (es) Nuevas composiciones farmacèuticas para el tratamiento de trastornos hiperproliferativos
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
BRPI0606542A2 (pt) métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
CL2008002130A1 (es) Compuestos derivados de 2-amino-cromen-4-ona; composicion farmaceutica que lo comprende; y uso en el tratamiento de una enfermedad que es aliviada por la inhibicion de la proteina quinasa dependiente de adn (adn-pk), tal como cancer.
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
CO6491052A2 (es) Compuestos espirociclicos que contienen notrogeno y su uso medicinal
EA201300213A1 (ru) Применение ингибиторов dpp iv
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
BR112013017722A2 (pt) combinação
DOP2010000301A (es) Compuestos de anillo fusionados y uso de los mismos
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
BRPI0506888A (pt) composições de suplemento lìquido compreendendo um ou mais medicamentos

Legal Events

Date Code Title Description
FC Refusal